Vitamin D modulates systemic inflammation in patients with severe COVID-19.

Autor: Sharif-Askari FS; Sharjah Institute of Medical Research, University of Sharjah, Sharjah, United Arab Emirates., Hafezi S; Sharjah Institute of Medical Research, University of Sharjah, Sharjah, United Arab Emirates., Sharif-Askari NS; Sharjah Institute of Medical Research, University of Sharjah, Sharjah, United Arab Emirates., Alsayed HAH; Pharmacy Department, Dubai Health Authority, Dubai, United Arab Emirates., Mdkhana B; Sharjah Institute of Medical Research, University of Sharjah, Sharjah, United Arab Emirates., Selvakumar B; Sharjah Institute of Medical Research, University of Sharjah, Sharjah, United Arab Emirates., Temsah MH; Immunology Research Lab, Department of Pediatrics, College of Medicine, King Saud University, Saudi Arabia., Saddik B; Sharjah Institute of Medical Research, University of Sharjah, Sharjah, United Arab Emirates; Department of Family and Community Medicine, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates., Al Anouti F; Department of Health Sciences, Zayed University, Abu Dhabi, United Arab Emirates., Halwani R; Sharjah Institute of Medical Research, University of Sharjah, Sharjah, United Arab Emirates; Department of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates; Prince Abdullah Ben Khaled Celiac Disease Chair, Department of Pediatrics, Faculty of Medicine, King Saud University, Saudi Arabia. Electronic address: rhalwani@sharjah.ac.ae.
Jazyk: angličtina
Zdroj: Life sciences [Life Sci] 2022 Oct 15; Vol. 307, pp. 120909. Date of Electronic Publication: 2022 Aug 24.
DOI: 10.1016/j.lfs.2022.120909
Abstrakt: Aims: The ability of vitamin D (VitD) to modulate immune responses in the clinical setting of COVID-19 infection is not well investigated. This study aimed to evaluate the ability of VitD to attenuate inflammatory responses in patients with severe COVID-19.
Materials and Methods: Blood samples and nasopharyngeal swabs were obtained from patients with severe COVID-19 who had been treated (20 patients), or not (25 patients), with VitD, during their stay in the intensive care unit. Western blotting was used to evaluate the expressions of STAT3, JNK and AKT signaling pathways and ELISA was used to measure levels of IL-6, IL-17, and IL-1β in blood of these patients.
Key Findings: Reduced levels of STAT3, JNK and AKT pathways and lower levels of proinflammatory cytokines such as IL-6, IL-17, and IL-1β were observed in VitD treated patients (50,000 IU of cholecalciferol weekly for 3 weeks), and in vitro following treatment of poly I:C stimulated PBMCs with VitD (50 nM of calcitriol). Moreover, lower circulatory levels of these proinflammatory cytokines following treatment with VitD were associated with lower serum levels of COVID-19-related severity markers such as D-dimer and C-reactive proteins (P < 0.001) which in overall resulted in shorter length of ICU stay for VitD treated compared to untreated patients (18 days for VitD treated vs. 28 days for VitD untreated; P = 0.01).
Significance: This study reveals that VitD plays immunomodulatory role during COVID-19 infection, which further emphasizes the importance of maintaining a normal level of this vitamin for the prevention of hyperinflammatory conditions associated with COVID-19.
Competing Interests: Declaration of competing interest All authors declare that they don't have any conflict of interests.
(Copyright © 2022 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: